What's New

Last Posted: Mar 07, 2023

• Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with BRAF Mutation.
  Suh Min Song, et al. Annals of dermatology 2021 0 (5) 556-561
• Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival.
  Tas Faruk, et al. Pathobiology : journal of immunopathology, molecular and cellular biology 2018 0 (4) 227-231
• Intratumor Heterogeneity of KIT Gene Mutations in Acral Lentiginous Melanoma.
  Comodo-Navarro Andréia Neves, et al. The American Journal of dermatopathology 2019 0 (4) 265-271
• Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K.
  Fernandes Mariana, et al. The American Journal of dermatopathology 2019 0 (10) 733-740
• MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project.
  Caini Saverio, et al. Melanoma research 2020 0 (5) 500-510
• Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.
  Andrieu Charlotte, et al. Medical sciences (Basel, Switzerland) 2022 0 (2)
• BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center.
  Ren Min, et al. Annals of translational medicine 2022 0 (2) 31
• Human leukocyte antigen Class II alleles associated with acral lentiginous melanoma in Mexican Mestizo patients: A case-control study.
  Roldan-Marin Rodrigo, et al. Indian journal of dermatology, venereology and leprology 2021 12 1-7
• Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
  Jamerson Taylor, et al. Journal of the National Medical Association 2021 9
• 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
  Tovar-Parra David, et al. In vivo (Athens, Greece) 0 0 (3) 1529-1536
• Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
  Gutiérrez-Castañeda Luz D, et al. BioMed research international 2020 0 2046947
• BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
  Dika Emi, et al. American journal of clinical pathology 2020 2
• Augmented Decision Making for Acral Lentiginous Melanoma Detection Using Deep Convolutional Neural Networks.
  Lee S et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2020 Jan
• BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
  Yilmaz Ismail, et al. Indian journal of pathology & microbiology 0 0 (3) 279-84
• Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
  Baiter Mirjam, et al. Dermatology (Basel, Switzerland) 2015 0 (2) 127-33
• Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study.
  Hong Jin-Woo, et al. Annals of dermatology 2014 4 (2) 195-202
• KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
  Zebary A, et al. Journal of dermatological science 2013 8
• Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.
  Puig-Butillé JA, et al. Experimental dermatology 2013 2 (2) 2
• Acral lentiginous melanoma
  From NCATS Genetic and Rare Diseases Information Center